Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatic stellate cell (HSC) contraction is a process where HSCs generate contractile force, regulating sinusoidal blood flow and contributing to liver fibrosis. Activated HSCs contract, narrowing sinusoids and increasing portal pressure. Contraction is driven by myosin II activation (Rho/Rho kinase pathway) and calcium signaling. Agonists like endothelin-1 and angiotensin-II promote contraction, while nitric oxide (NO) and other factors induce relaxation. HSC contraction is a therapeutic target for portal hypertension and liver fibrosis.
Modulation of HSC contractile machinery (myosin II activation via Rho/Rho kinase pathway) and/or calcium signaling. Augmentation of relaxation factors like nitric oxide.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatic Stellate Cell Contraction (HSC Contraction).